Search research articles
Contact Us
Filters
Showing results (181-190 of 323) with videos related to
Page
of 33
Sort By:
British Journal of Haematology
|
February 28, 2020
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia
Cristina Jiménez, Gloria G Chan, Lian Xu, et al.
Molecular Cancer Therapeutics
|
January 17, 2012
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma
Douglas W McMillin, Hannah M Jacobs, Jake E Delmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Steven P Treon, Kirsten Meid, Joshua Gustine, et al.
Blood
|
July 22, 2021
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Marit Jalink, Sigbjørn Berentsen, Jorge J Castillo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2011
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia
Bryan T Ciccarelli, Christopher J Patterson, Zachary R Hunter, et al.
Journal of Medicinal Chemistry
|
January 3, 2026
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies
John M Hatcher, Shirong Liu, Amanda Kofides, et al.
American Journal of Hematology
|
September 7, 2006
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia
Xavier Leleu, Kelly O'Connor, Allen W Ho, et al.
Seminars in Hematology
|
May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia
Shayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
American Journal of Hematology
|
July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
Irene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.
Blood Advances
|
September 21, 2020
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia
Cristina Jiménez, Lian Xu, Nickolas Tsakmaklis, et al.
Page
of 33
Search research articles
Search
Showing results (181-190 of 323) with videos related to
Sort By:
Page
of 33
British Journal of Haematology
|
February 28, 2020
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia
Cristina Jiménez, Gloria G Chan, Lian Xu, et al.
Molecular Cancer Therapeutics
|
January 17, 2012
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma
Douglas W McMillin, Hannah M Jacobs, Jake E Delmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Steven P Treon, Kirsten Meid, Joshua Gustine, et al.
Blood
|
July 22, 2021
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Marit Jalink, Sigbjørn Berentsen, Jorge J Castillo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2011
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia
Bryan T Ciccarelli, Christopher J Patterson, Zachary R Hunter, et al.
Journal of Medicinal Chemistry
|
January 3, 2026
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies
John M Hatcher, Shirong Liu, Amanda Kofides, et al.
American Journal of Hematology
|
September 7, 2006
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia
Xavier Leleu, Kelly O'Connor, Allen W Ho, et al.
Seminars in Hematology
|
May 25, 2025
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia
Shayna Sarosiek, Anne-Marie L Becking, Andrew Branagan, et al.
American Journal of Hematology
|
July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
Irene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.
Blood Advances
|
September 21, 2020
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia
Cristina Jiménez, Lian Xu, Nickolas Tsakmaklis, et al.
Page
of 33